Seawolf Therapeutics Raises $100M Across Seed and Series A for Redosable DNA Medicines
Gene therapy has a one-shot problem. Most of today's approaches use AAV viruses, and once your immune system has seen the vector, a second dose usually stops working. Seawolf Therapeutics, a San Diego company founded in 2021, came out of stealth Monday with $100M across a seed and a Series A to sell the opposite: DNA medicines you can dose again, as rarely as every six to twelve months. Release: https://seawolftx.com/seawolf-therapeutics-debuts-with-100-million-to-advance-dna-based-therapeutics/ and Fierce Biotech https://www.fiercebiotech.com/biotech/dna-delivery-biotech-seawolf-surfaces-alongside-investors-novartis-lilly-and-partner-sanofi
The seed was led by Versant Ventures. The Series A brought in Eli Lilly and the Novartis Venture Fund, alongside Versant, MPM BioImpact, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures from the National Bleeding Disorders Foundation. How the $100M splits between the two rounds was not disclosed, and neither was a valuation.
The platform is called Trident. In plain terms: a lipid nanoparticle carries a DNA payload built to provoke less of an immune response, plus a helper protein that gets the DNA into the cell nucleus. The lead program is in metabolic disease. Founder and CEO Elizabeth Alcamo runs the company.
The same day, Sanofi signed a multi-target research collaboration and exclusive license covering bleeding disorders and undisclosed targets, worth up to $1.2B in milestones plus tiered royalties. That is the real signal: two big pharma investors on the cap table and a third paying for access before any clinical data. Milestone totals are best-case numbers, so read the $1.2B as a ceiling, not a check.
← Back to all articles
The seed was led by Versant Ventures. The Series A brought in Eli Lilly and the Novartis Venture Fund, alongside Versant, MPM BioImpact, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures from the National Bleeding Disorders Foundation. How the $100M splits between the two rounds was not disclosed, and neither was a valuation.
The platform is called Trident. In plain terms: a lipid nanoparticle carries a DNA payload built to provoke less of an immune response, plus a helper protein that gets the DNA into the cell nucleus. The lead program is in metabolic disease. Founder and CEO Elizabeth Alcamo runs the company.
The same day, Sanofi signed a multi-target research collaboration and exclusive license covering bleeding disorders and undisclosed targets, worth up to $1.2B in milestones plus tiered royalties. That is the real signal: two big pharma investors on the cap table and a third paying for access before any clinical data. Milestone totals are best-case numbers, so read the $1.2B as a ceiling, not a check.
Comments